![IQVIA will partner with Genomics England to develop a platform designed to allow researchers to create custom clinical-genomic datasets and run advanced analytics on genomics and observable traits by combining IQVIA’s E360 healthcare analytics platform (pictured) with Genomics England’s patient data. [Source: IQVIA]](https://www.insideprecisionmedicine.com/wp-content/uploads/2019/01/1925-696x247.jpeg "IQVIA will partner with Genomics England to develop a platform designed to allow researchers to create custom clinical-genomic datasets and run advanced analytics on genomics and observable traits by combining IQVIA’s E360 healthcare analytics platform (pictured) with Genomics England’s patient data. [Source: IQVIA]")
IQVIA said today it will partner with Genomics England to develop a platform designed to integrate clinical and de-identified genomics data, through a collaboration whose value was not disclosed.
IQVIA said the collaboration will allow researchers to create custom clinical-genomic datasets and run advanced analytics on genomics and observable traits by combining IQVIA’s E360 healthcare analytics platform with Genomics England’s patient data, which the program says is de-identified and generated with their consent.
E360 is designed to facilitate data exploration and discovery, clinical development, health economics and outcomes research (HEOR), as well as rapid and actionable market insights.
The collaboration, according to IQVIA, is intended to advance precision medicine by enabling faster and more efficient drug research, as well as stronger evidence intended to support treatment value.
“Drawing insights from clinical-genomics datasets is the future of real-world research, and we are delighted to work alongside Genomics England as a pioneer in this evolving field,” Jon Resnick, president, IQVIA Real-World and Analytics Solutions, said in a statement. “Our collaboration advances the analysis of these complex datasets, which could accelerate the discovery of precision therapies, improve access and health outcomes, and deliver upon our Human Data Science vision.”
The company said its partnership with Genomics England also holds potential for catalyzing analytic and scientific advances and thus enhancing the attractiveness of the United Kingdom to investors—key concerns to the kingdom’s life sciences stakeholders given the planned “Brexit” departure from the European Union, with the U.K.’s Medicines and Healthcare Products Regulatory Agency insisting that the kingdom “remains a fantastic place for innovation.”
IQVIA—which changed its name last year from QuintilesIMS—provides advanced analytics, technology solutions and contract research services to the life sciences industry.
“IQVIA brings together deep healthcare and life sciences domain expertise to manage and curate real-world data with advanced analytical technologies. Working together, we can unlock the potential of these datasets to advance research and benefit patients in the U.K. as well as those throughout the world,” added Joanne Hackett, Genomics England’s, chief commercial officer.
Genomics England was formed in 2013 by the U.K. Department of Health to run the 100,000 Genomes Project, an effort to collect, store, and analyze data from the genomes of patients with rare diseases, their families, and patients with cancer. The 100,000 Genomes Project is among initiatives launched by 10 nations worldwide toward gathering, storing, and applying genomic data from at least 100,000 genomes.
